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tive	 and	 severe	 infection	 (associated	 with	 hospitalization/mortality)	 in	 those	 with	





2282	had	 severe	 infection	by	 end	of	 January	2021.	 In	 unadjusted	models,	 partici-
pants	with	≥2	family	members	with	diabetes	were	more	likely	to	be	SARS-	CoV-	2	posi-
tive	(risk	ratio-	RR	1.35;	95%	confidence	interval-	CI	1.24–	1.47)	and	severe	infection	
(RR	1.30;	95%	CI	1.04–	1.59),	 compared	 to	 those	without.	The	excess	 risk	of	being	
tested	positive	for	SARS-	CoV-	2	was	attenuated	but	significant	after	adjusting	for	de-
mographics,	lifestyle	factors,	multimorbidity	and	presence	of	cardiometabolic	condi-
tions.	The	excess	 risk	 for	 severe	 infection	was	no	 longer	significant	after	adjusting	
for	demographics,	lifestyle	factors,	multimorbidity	and	presence	of	cardiometabolic	
conditions,	and	was	absent	when	excluding	incident	diabetes.
Conclusion: The totality of the results suggests that good lifestyle and not developing 
incident diabetes may lessen risks of severe infections in people with a strong family 
of diabetes.
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1  |  INTRODUC TION
People	with	existing	health	 conditions	 are	 at	higher	 risk	of	 SARS-	




Family	 history	 (parental	 or	 sibling)	 of	 diabetes	 is	 a	 strong	 risk	
factor	for	type	2	diabetes,	with	stronger	familiality	(ie	>one family 




The	 risk	 for	 SARS-	CoV-	2	 infection	 and	 poor	 outcomes	 among	
those with family history of diabetes has not been previously inves-




portant to know as diabetes can be prevented. We investigated the 
association of family history of diabetes with the risk of developing 
SARS-	CoV-	2	and	severe	SARS-	CoV-	2,	and	the	potential	role	of	de-
mographic and lifestyle factors in such a link.
2  |  METHODS
2.1  |  Ethical approval
This	 study	 was	 conducted	 as	 part	 of	 UK	 Biobank	 project	 num-
ber	 14151	 and	 is	 covered	 by	 the	 generic	 ethics	 approval	 for	 UK	
Biobank	studies	from	the	NHS	National	Research	Ethics	Service	(16/
NW/0274).	 All	 participants	 gave	written	 informed	 consent	 before	
enrolment	in	the	study,	which	was	conducted	in	accordance	with	the	
principles of the Declaration of Helsinki.
2.2  |  Study design
We	 used	 data	 from	UK	 Biobank	 (UKB),	 a	 longitudinal	 cohort	 of	
502,503	 participants	 aged	 37–	73	 recruited	 from	 the	 general	
population	 in	 England,	 Wales	 and	 Scotland	 between	 2006	 and	
2010.	 SARS-	CoV-	2	 test	 samples	 were	 collected	 and	 processed	
between	16th	March	2020	and	31st	 January	2021.	SARS-	CoV-	2	
test	 results	 were	 provided	 by	 Public	 Health	 England	 (http://
bioba	nk.ndph.ox.ac.uk/ukb/exinfo.cgi?src=COVID	19_tests).	
Participants	who	 had	 died	 prior	 to	 the	 SARS-	CoV-	2	 outbreak	 in	
the	UK	 (01/03/2020)	 and	who	 reported	 diabetes	 at	 the	 time	of	
UKB	study	recruitment	were	excluded.	Data	were	only	available	
for participants in England. During the early study period of the 
‘first	wave’	of	 the	outbreak	 in	England,	SARS-	CoV-	2	 testing	was	
highly selective and limited to only those participants who pre-
sented with severe symptoms.
2.3  |  Exposure variable
Family	 history	 of	 diabetes	 (mother/father/sibling)	was	 reported	 at	
the	time	of	 recruitment	and	categorized	 into	none,	one,	or	 two	or	
more,	according	to	the	number	of	family	members	with	a	history	of	
diabetes.
2.4  |  Outcome variables
Confirmed	SARS-	CoV-	2	 infection	 (≥one	positive	result)	and	severe	
SARS-	CoV-	2	 infection	 (defined	 as	 testing	 positive	 during	 an	 inpa-
tient hospital episode).
2.5  |  Sociodemographics, lifestyle and underlying 
health conditions
Age	 at	 recruitment	 was	 used	 as	 a	 continuous	 variable.	 Sex	 and	
ethnicity	 (categorized	 into	 ‘Asian	 or	 Asian	 British’,	 ‘Black	 or	 Black	




study	 recruitment	 was	 categorized	 as	 never,	 previous	 or	 current.	
Body	mass	index	(BMI)	was	measured	by	a	study	nurse	at	the	time	
of	UKB	study	recruitment	and	used	as	a	continuous	variable.	Level	
of	 physical	 activity	was	 defined	 as	 ‘none’,	 ‘low’,	 ‘medium’	 or	 ‘high’	
using	Metabolic	Equivalent	of	Task	(MET)	minutes	per	week	scores	
based	 on	 the	 International	 Physical	 Activity	Questionnaire	 (IPAQ)	
scoring	 protocol	 2005.	 The	physical	 and	mental	 health	 conditions	
self-	reported	by	participants	at	the	time	of	UKB	study	recruitment	
were	organized	 into	a	 list	of	43	 long-	term	conditions	 (LTCs)	based	
on our previously published literature.7,8	Multimorbidity	count	was	
classified	by	LTC	count	 into	0,	1,	2,	3	or	≥4.	Presence	of	 four	car-
diometabolic	 conditions	 (hypertension,	 diabetes,	 ischaemic	 heart	
disease	and	stroke)	was	ascertained	via	participant	self-	report	at	the	
time	 of	UKB	 study	 recruitment	 or	 hospitalization	 event	 (between	
UKB	study	recruitment	to	April	2019)	with	ICD-	10	codes	as	primary	
or	secondary	discharge	diagnoses	(incident).
2.6  |  Statistical analysis
We used Poisson regression models with robust standard errors to 
test	for	cross-	sectional	associations	between	family	history	of	dia-
betes	and	SARS-	CoV-	2	infection	or	severe	SARS-	CoV-	2.	Unadjusted	




cardiovascular	conditions	at	 the	 time	of	 study	 recruitment	 (hyper-
tension,	ischaemic	heart	disease	and	stroke),	incident	admissions	for	
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cardiometabolic	conditions	(hypertension,	diabetes,	ischaemic	heart	
disease and stroke) and multimorbidity count.
2.7  |  Sensitivity analysis
The main analysis was repeated for the subset of participants 









(please	 see	Figure	1).	On	 recruitment,	 70,427	participants	 (17.5%)	
reported	 having	 one	 family	 member	 with	 diabetes,	 and	 12,443	
(3.1%)	reported	having	two	or	more	family	members	with	diabetes	
(Table	1).
In	 total,	13,331	 (3.32%)	 tested	positive	 for	SARS-	CoV-	2	and	
2282	 (0.6%)	 participants	 had	 severe	 SARS-	CoV-	2	 (ie	 infection	
detected in hospital or through death). The proportion of study 
sample	testing	positive	of	SARS-	CoV-	2	infection	was	3.2%,	3.65%	
and	4.33%	respectively	for	those	with	no,	one	and	two	or	more	
family members with diabetes. Participants with at least one 





have	severe	 infection	 (RR	1.30;	95%	CI	1.04–	1.59)	 than	partici-
pants with no family history. The association with risk of testing 
positive was attenuated after adjusting for sociodemographics 
(RR	1.17;	95	CI	1.07–	1.27),	 and	 additionally	 for	 lifestyle	 factors	




and two or more family members with diabetes. Participants with 
two or more family members with diabetes were more likely to 
have	 severe	 SARS-	CoV-	2	 infection	 (RR	 1.30;	 95%	CI	 1.04–	1.59)	
in unadjusted model. The association was no longer significant 
after	adjusting	for	demographics,	lifestyle	factors	and	underlying	
health.
3.1  |  Sensitivity analysis
Table 2 shows the results of association between family history 
of	 diabetes	 and	 risk	 of	 severe	 SARS-	CoV-	2	 only	 for	 the	 subset	 of	
participants	who	were	tested	positive	for	SARS-	CoV-	2.	The	results	
show that there was no significant association between family his-
tory	of	diabetes	and	severe	SARS-	CoV-	2	 in	the	subset	who	tested	
positive.	Table	3	shows	 the	 results	of	 sensitivity	analysis	after	ex-
cluding	 participants	who	were	 diagnosed	with	 diabetes	 (based	on	
hospitalization	records)	since	the	study	recruitment	to	the	onset	of	
COVID	pandemic.	 In	 the	 sensitivity	 analysis,	 there	was	 significant	
association between family history of diabetes and testing positive 





Given	diabetes	 is	a	strong	prognostic	 factor	 for	SARS-	CoV-	2	se-
verity	and	mortality,9 relatives of such patients may be rightly con-
cerned that they are also at higher risk. The present analyses have 
shown	this	to	be	the	case	with	a	35%	higher	chance	of	a	positive	
SARS-	CoV-	2	test	and	a	30%	higher	chance	of	severe	SARS-	CoV-	2	






higher	 risk	of	 severe	SARS-	CoV-	2	with	physical	 inactivity,	 smok-
ing and obesity but not heavy alcohol consumption.10	In	addition,	
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mendelian	randomization	approach.11 Hopkinson et al. found that 
people who smoke were at higher risk of developing symptomatic 





We	accept	 some	 limitations.	UK	Biobank	participants	are	 rela-
tively	 healthier	 and	more	 affluent	 than	 general	UK	 population	 al-
though there is some evidence that risk factor associations with 
health	outcomes	are	generalizable.14 The work did not differentiate 
between	type	1	and	type	2	diabetes,	though	most	with	two	family	
members are likely to have Type 2 diabetes. The data on family his-





were collected more than 10 years ago. During the early study pe-
riod	of	the	‘first	wave’	of	the	outbreak	in	England,	SARS-	CoV-	2	test-
ing was highly selective and limited to only those participants who 
presented with severe symptoms. There was no association found 
between	 family	 history	 of	 diabetes	 and	 severe	 SARS-	CoV-	2	 risk	







believe our main findings hold relevance to those with family histo-
ries of diabetes.
The	 association	of	 being	 SARS-	CoV-	2	 positive	with	 family	 his-
tory of diabetes may partially reflect both a strong association be-
tween	 excess	 body	 weight	 and	 SARS-	CoV-	2	 infection	 or	 related	
mortality	 (as	recently	summarized	 in	a	UK	Governmental	 report)15 
and	the	strong	social	factors	(ie	lower	socioeconomic	status)	linked	
to	 SARS-	CoV-	2	 infection	 that	 overlap	with	 diabetes	 risk.	 The	 risk	
attenuation after adjustment for lifestyle factors provides some re-
assurance that healthy lifestyle may not only attenuate risk of diabe-
tes in those with strong family histories but may also attenuate risk 
of	 SARS-	CoV-	2	 disease	 and	 severe	 complications.	 The	 sensitivity	
analyses	also	point	in	similar	direction.	However,	this	attenuation	in	
risk is likely related to lifestyle over many years and so our findings 
do	not	necessarily	demonstrate	that	short-	term	change	 in	 lifestyle	
would	immediately	alter	the	risk	of	SARS-	CoV-	2	infection,	although	
such	 short-	term	 changes	 can	 prevent	 diabetes.	 Our	 findings	 may	
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